Sheba’s extensive experience with CAR T-cell therapy speaks louder than words. Led by Prof. Arnon Nagler, President of the Hemato-Oncology Center and a world-renowned specialist in the field, we have provided over 220 patients with CAR-T therapy, including about 60 children.

CAR-T therapy at Sheba is all-inclusive. That means all stages of the process are done on campus, including blood harvesting, genetic engineering of the cells, T-cell injections, and patient observation. The patient experience is therefore as convenient and comfortable as possible.

CARs are more readily available at Sheba because the cells are engineered at an on-site laboratory, a process that only takes about 10 days to complete. In contrast, other medical centers use commercial CARs that must be shipped overseas for engineering, so the entire process, from lymphocyte collection to delivery, can take weeks or even months. The extra wait-time not only gives the disease time to progress, but also reduces the chances of a positive patient response to the CARs.

The physicians at Sheba are some of the most experienced in the world in the field of CAR-T therapy. Prof. Nagler, a renowned expert on the topic, is one of the three board members of the organizing committee for the largest European conference held annually on CAR T-cell therapy.